Klaria Pharma Holding Stock Current Valuation
| KLAR Stock | SEK 0.36 0.02 5.26% |
Valuation analysis of Klaria Pharma Holding helps investors to measure Klaria Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Klaria Pharma's price fluctuation is out of control at this time. Calculation of the real value of Klaria Pharma Holding is based on 3 months time horizon. Increasing Klaria Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Klaria Pharma Holding is useful when determining the fair value of the Klaria stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Klaria Pharma. Since Klaria Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Klaria Stock. However, Klaria Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.36 | Real 0.29 | Hype 0.36 |
The real value of Klaria Stock, also known as its intrinsic value, is the underlying worth of Klaria Pharma Holding Company, which is reflected in its stock price. It is based on Klaria Pharma's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Klaria Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Klaria Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Klaria Pharma Holding helps investors to forecast how Klaria stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Klaria Pharma more accurately as focusing exclusively on Klaria Pharma's fundamentals will not take into account other important factors: Klaria Pharma Holding Company Current Valuation Analysis
Klaria Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Klaria Pharma Current Valuation | 88.14 M |
Most of Klaria Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Klaria Pharma Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Klaria Pharma Holding has a Current Valuation of 88.14 M. This is 99.39% lower than that of the Healthcare sector and 98.81% lower than that of the Drug Manufacturers - Specialty & Generic industry. The current valuation for all Sweden stocks is 99.47% higher than that of the company.
Klaria Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Klaria Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Klaria Pharma could also be used in its relative valuation, which is a method of valuing Klaria Pharma by comparing valuation metrics of similar companies.Klaria Pharma is currently under evaluation in current valuation category among related companies.
Klaria Fundamentals
| Return On Equity | -0.88 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (9.48) % | |||
| Current Valuation | 88.14 M | |||
| Shares Outstanding | 63.1 M | |||
| Shares Owned By Insiders | 10.73 % | |||
| Shares Owned By Institutions | 9.75 % | |||
| Price To Earning | (18.43) X | |||
| Price To Book | 1.42 X | |||
| Price To Sales | 8.00 X | |||
| Gross Profit | 5.87 M | |||
| EBITDA | (39.41 M) | |||
| Net Income | (53.53 M) | |||
| Cash And Equivalents | 25.49 M | |||
| Cash Per Share | 0.47 X | |||
| Total Debt | 1.02 M | |||
| Current Ratio | 0.68 X | |||
| Book Value Per Share | 0.97 X | |||
| Cash Flow From Operations | (24.8 M) | |||
| Earnings Per Share | (1.72) X | |||
| Beta | 0.39 | |||
| Market Capitalization | 39.49 M | |||
| Total Asset | 118.31 M | |||
| Retained Earnings | (9 M) | |||
| Working Capital | 41 M | |||
| Current Asset | 44 M | |||
| Current Liabilities | 3 M | |||
| Z Score | 22.8 | |||
| Net Asset | 118.31 M |
About Klaria Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Klaria Pharma Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Klaria Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Klaria Pharma Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Klaria Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Klaria Pharma's short interest history, or implied volatility extrapolated from Klaria Pharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Klaria Pharma Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Klaria Stock analysis
When running Klaria Pharma's price analysis, check to measure Klaria Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Klaria Pharma is operating at the current time. Most of Klaria Pharma's value examination focuses on studying past and present price action to predict the probability of Klaria Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Klaria Pharma's price. Additionally, you may evaluate how the addition of Klaria Pharma to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |